吉西他滨联合顺铂治疗晚期三阴乳腺癌近期疗效观察

目的探讨吉西他滨联合顺铂一线治疗晚期三阴性乳腺癌的临床疗效及不良反应。方法 30例晚期三阴性乳腺癌患者,采用吉西他滨联合顺铂一线放疗治疗,2个周期后评价治疗效果及不良反应。结果 30例患者均可评价疗效,其中完全缓解（CR）2例（6.7%）,部分缓解（PR）8例（26.6%）,稳定（SD）11例（36.7%）,进展（PD）9例（30.0%）,总有效率（CR＋PR）33.3%,随访1年,中位疾病进展时间5.4个月,主要不良反应为胃肠道反应、骨髓抑制,Ⅲ-Ⅳ级不良反应主要是中性粒细胞减少、血小板减少,无化疗相关死亡病例。结论吉西他滨联合顺铂治疗晚期三阴性乳腺癌近期疗效较好,不良反应可耐受,是晚期三阴性乳腺癌的有效治疗方案。

Effect of Gemcitabine and Cisplatin in the Treatment of Advanced Triple-negative Breast Cancer

Objective To observe the effect of Gemcitabine and Cisplatin in the treatment of advanced triple- negative breast cancer.Methods 30 patients with advanced triple- negative breast cancer were treated by Gemcitabine and Cisplatin. The effects were observed after at least 2 weeks＇ therapy. Results All 30 patients were available for objective response,CR 2 cases（ 6. 7%）,PR 8 cases（ 26. 6%）,SD 11 cases（ 36. 7%）,PD 9 cases（ 30. 0%）,and the overall response rate（ CR ＋ PR） was 33. 3%. After 1 year＇s follow- up,the median survival duration was 5. 4 months; the main treatment- related toxicities were bone marrow depression and gastrointestinal reaction.Grade Ⅲ - Ⅳ toxicity mainly included neutropenia and thrombocytopenia,and there was no related death disease. Conclusion Gemcitabine combined with cisplatin is effective in the treatment of patients with advanced breast cancer with acceptable toxic reaction. It may be an effective regimen.